SCHEMBL140715

SCHEMBL140715

CN(C)CCNC(=O)c1ccc2[nH]c3c(C(N)=O)cc(-c4ccc(Cl)cc4)cc3c2c1

nearest known ligand 0.83

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 14/20 0.83
BTK Q06187 5/20 0.58
JAK1 P23458 5/20 0.58
TYK2 P29597 5/20 0.58
JAK3 P52333 5/20 0.58
TLR9 Q9NR96 2/20 0.49
TLR8 Q9NR97 2/20 0.49
TLR7 Q9NYK1 2/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CACNA1G O43497 1/20 0.47
KMT2A Q03164 1/20 0.47
HRH4 Q9H3N8 1/20 0.45
HRH3 Q9Y5N1 1/20 0.45
PARP1 P09874 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL147444 0.91 JAK2 (1.00) JAK2BTKJAK1TYK2JAK3
SCHEMBL143466 0.88 JAK2 (0.65) JAK2BTKJAK1TYK2JAK3
SCHEMBL178678 0.84 JAK2 (0.72) JAK2BTKJAK1TYK2JAK3
SCHEMBL140120 0.80 JAK2 (0.58) JAK2BTKJAK1TYK2JAK3
SCHEMBL141825 0.80 JAK2 (0.80) JAK2BTKJAK1TYK2JAK3
SCHEMBL178682 0.79 JAK2 (0.80) JAK2BTKJAK1TYK2JAK3
SCHEMBL143613 0.79 JAK2 (0.79) JAK2BTKJAK1TYK2JAK3
SCHEMBL141767 0.77 JAK2 (0.62) JAK2JAK1TYK2JAK3TLR9
SCHEMBL15800313 0.76 JAK2 (0.75) JAK2BTKJAK1TYK2JAK3
SCHEMBL178699 0.76 JAK2 (1.00) JAK2BTKJAK1TYK2JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885BTK 79/4885JAK1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.